Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hypertension

  Free Subscription


Articles published in Eur J Pharmacol

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    July 2022
  1. KODAMA T, Otani K, Okada M, Yamawaki H, et al
    Eukaryotic elongation factor 2 kinase inhibitor, A484954 inhibits perivascular sympathetic nerve stimulation-induced vasoconstriction in isolated renal artery.
    Eur J Pharmacol. 2022;926:175042.
    PubMed     Abstract available


  2. WANG C, Han L, Wang T, Wang Y, et al
    Cyclosporin A up-regulated thromboxane A2 receptor through activation of MAPK and NF-kappaB pathways in rat mesenteric artery.
    Eur J Pharmacol. 2022;926:175034.
    PubMed     Abstract available


  3. IQBAL H, Yadav P, Verma AK, Mishra D, et al
    Anti-inflammatory, anti-oxidant and cardio-protective properties of novel fluorophenyl benzimidazole in L-NAME-induced hypertensive rats.
    Eur J Pharmacol. 2022 Jul 2:175132. doi: 10.1016/j.ejphar.2022.175132.
    PubMed     Abstract available


    June 2022
  4. ZHAO X, Li L, Li S, Liu J, et al
    Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3.
    Eur J Pharmacol. 2022 Jun 20:175115. doi: 10.1016/j.ejphar.2022.175115.
    PubMed     Abstract available


  5. LI XT, Zhang YP, Zhang MW, Zhang ZZ, et al
    Sirtuin 7 serves as a promising therapeutic target for cardiorenal diseases.
    Eur J Pharmacol. 2022;925:174977.
    PubMed     Abstract available


    May 2022
  6. LI L, Su XL, Bai TT, Qin W, et al
    New paeonol derivative C302 reduces hypertension in spontaneously hypertensive rats through endothelium-dependent and endothelium-independent vasodilation.
    Eur J Pharmacol. 2022 May 27:175057. doi: 10.1016/j.ejphar.2022.175057.
    PubMed     Abstract available


  7. BANKS TE, Rajapaksha M, Zhang LH, Bai F, et al
    Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
    Eur J Pharmacol. 2022 May 26:175048. doi: 10.1016/j.ejphar.2022.175048.
    PubMed     Abstract available


  8. JOO TURONI CM, Maranon RO, Alberstein RA, Sanchez RS, et al
    A novel endothelium-independent effect of insulin on basal vascular tone in cafeteria diet-induced hypertensive rats.
    Eur J Pharmacol. 2022;925:174997.
    PubMed     Abstract available


    March 2022
  9. SHIMIZU S, Nagao Y, Kurabayashi A, Shimizu T, et al
    Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats.
    Eur J Pharmacol. 2022 Mar 22:174911. doi: 10.1016/j.ejphar.2022.174911.
    PubMed     Abstract available


    January 2022
  10. CHEN D, Yuan T, Chen Y, Zhang H, et al
    DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
    Eur J Pharmacol. 2022 Jan 26:174779. doi: 10.1016/j.ejphar.2022.174779.
    PubMed     Abstract available


    December 2021
  11. DIAS CJ, Costa HA, Alves Dias-Filho CA, Ferreira AC, et al
    Carvacrol reduces blood pressure, arterial responsiveness and increases expression of MAS receptors in spontaneously hypertensive rats.
    Eur J Pharmacol. 2021 Dec 22:174717. doi: 10.1016/j.ejphar.2021.174717.
    PubMed     Abstract available


  12. ZHENG L, Zhao Z, Lin J, Li H, et al
    Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.
    Eur J Pharmacol. 2021 Dec 20:174713. doi: 10.1016/j.ejphar.2021.174713.
    PubMed     Abstract available


  13. TOBA H, Ikemoto MJ, Kobara M, Nakata T, et al
    Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive r
    Eur J Pharmacol. 2021 Dec 3:174681. doi: 10.1016/j.ejphar.2021.174681.
    PubMed     Abstract available


    November 2021
  14. KODAMA T, Kameshima S, Otani K, Okada M, et al
    Eukaryotic elongation factor 2 kinase inhibitor, A484954 induces diuretic effect via renal vasorelaxation in spontaneously hypertensive rats.
    Eur J Pharmacol. 2021 Nov 18:174637. doi: 10.1016/j.ejphar.2021.174637.
    PubMed     Abstract available


    October 2021
  15. BALERA BRITO VG, Patrocinio MS, Alves Barreto AE, Tfaile Frasnelli SC, et al
    Telmisartan impairs the in vitro osteogenic differentiation of mesenchymal stromal cells from spontaneously hypertensive male rats.
    Eur J Pharmacol. 2021;912:174609.
    PubMed     Abstract available


    September 2021
  16. ALVES BARRETO AE, Balera Brito VG, Patrocinio MS, Ballassoni BB, et al
    beta1-adrenergic receptor but not beta2 mediates osteogenic differentiation of bone marrow mesenchymal stem cells in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Sep 20:174515. doi: 10.1016/j.ejphar.2021.174515.
    PubMed     Abstract available


  17. CORBOZ MR, Plaunt AJ, Malinin V, Li Z, et al
    Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Eur J Pharmacol. 2021 Sep 8:174484. doi: 10.1016/j.ejphar.2021.174484.
    PubMed     Abstract available


  18. BADZYNSKA B, Vaneckova I, Sadowski J, Hojna S, et al
    Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Sep 4:174445. doi: 10.1016/j.ejphar.2021.174445.
    PubMed     Abstract available


    August 2021
  19. HU J, Yang Z, Chen X, Kuang S, et al
    Thromboxane A2 is involved in the development of hypertension in chronic kidney disease rats.
    Eur J Pharmacol. 2021 Aug 17:174435. doi: 10.1016/j.ejphar.2021.174435.
    PubMed     Abstract available


  20. ARAUJO ENCINAS JF, Foncesca Peiro CH, Perez MM, Santos Raimundo JR, et al
    Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review.
    Eur J Pharmacol. 2021;905:174180.
    PubMed     Abstract available


    July 2021
  21. HUANG N, Zhu TT, Liu T, Ge XY, et al
    Aspirin ameliorates pulmonary vascular remodeling in pulmonary hypertension by dampening endothelial-to-mesenchymal transition.
    Eur J Pharmacol. 2021;908:174307.
    PubMed     Abstract available


  22. BATISTA RIM, Nogueira RC, Ferreira GC, Oliveira-Paula GH, et al
    Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine.
    Eur J Pharmacol. 2021;907:174314.
    PubMed     Abstract available


  23. LV Y, Ma P, Wang J, Xu Q, et al
    Betaine alleviates right ventricular failure via regulation of Rho A/ROCK signaling pathway in rats with pulmonary arterial hypertension.
    Eur J Pharmacol. 2021 Jul 7:174311. doi: 10.1016/j.ejphar.2021.174311.
    PubMed     Abstract available


    June 2021
  24. ZHU JX, Ling W, Xue C, Zhou Z, et al
    Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-beta1/Smad signaling.
    Eur J Pharmacol. 2021;900:174013.
    PubMed     Abstract available


    May 2021
  25. BUNBUPHA S, Prasarttong P, Poasakate A, Maneesai P, et al
    Imperatorin alleviates metabolic and vascular alterations in high-fat/high-fructose diet-fed rats by modulating adiponectin receptor 1, eNOS, and p47(phox) expression.
    Eur J Pharmacol. 2021;899:174010.
    PubMed     Abstract available


  26. DOGHRI Y, Dubreil L, Lalanne V, Helissen O, et al
    Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome.
    Eur J Pharmacol. 2021;899:173978.
    PubMed     Abstract available


    April 2021
  27. SILVA EAP, Carvalho JS, Dos Santos DM, Oliveira AMS, et al
    Cardiovascular effects of farnesol and its beta-cyclodextrin complex in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Apr 2:174060. doi: 10.1016/j.ejphar.2021.174060.
    PubMed     Abstract available


    March 2021
  28. SHI Y, Jiang R, Qin X, Gao A, et al
    Up-regulation of nPKC contributes to proliferation of mice pulmonary artery smooth muscle cells in hypoxia-induced pulmonary hypertension.
    Eur J Pharmacol. 2021 Mar 18:174046. doi: 10.1016/j.ejphar.2021.174046.
    PubMed     Abstract available


  29. POORGOLIZADEH E, Homayouni Moghadam F, Dormiani K, Rezaei N, et al
    Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!
    Eur J Pharmacol. 2021;894:173851.
    PubMed     Abstract available


    February 2021
  30. JASINSKA-STROSCHEIN M, Orszulak-Michalak D
    Reporting experimental studies on animals - The problems with translating of outcomes to clinical benefits. Methodological and statistical considerations: The example of pulmonary hypertension.
    Eur J Pharmacol. 2021;897:173952.
    PubMed     Abstract available


  31. GONZAGA-COSTA K, Vasconcelos-Silva AA, Rodrigues-Silva MJ, Rebouca CDSM, et al
    Soluble guanylate cyclase stimulator, trans-4-methoxy-beta-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
    Eur J Pharmacol. 2021;897:173948.
    PubMed     Abstract available


  32. ZHANG Y, Luo W, Li H, Yu G, et al
    Larger endothelium-dependent contractions in iliac arteries of adult SHRs are attributed to differential downregulation of TP and EP3 receptors in the vessels of WKYs and SHRs during the transition from adolescence to adulthood.
    Eur J Pharmacol. 2021;893:173828.
    PubMed     Abstract available


    November 2020
  33. LIU T, Hong L, Yang Y, Qiao X, et al
    Metformin reduces proteinuria in spontaneously hypertensive rats by activating the HIF-2alpha-VEGF-A pathway.
    Eur J Pharmacol. 2020 Nov 18:173731. doi: 10.1016/j.ejphar.2020.173731.
    PubMed     Abstract available


  34. ZIMMER A, Teixeira RB, Constantin RL, Campos-Carraro C, et al
    The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress, and impaired pulmonary artery reactivity.
    Eur J Pharmacol. 2020 Nov 5:173699. doi: 10.1016/j.ejphar.2020.173699.
    PubMed     Abstract available


  35. ESCUDERO DS, Brea MS, Caldiz CI, Amarillo ME, et al
    PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing sildenafil for the treatment of hypertensive cardiac hypertrophy.
    Eur J Pharmacol. 2020 Nov 2:173724. doi: 10.1016/j.ejphar.2020.173724.
    PubMed     Abstract available


    October 2020
  36. MULVANEY EP, Reid HM, Bialesova L, Mendes-Ferreira P, et al
    Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
    Eur J Pharmacol. 2020 Oct 26:173658. doi: 10.1016/j.ejphar.2020.173658.
    PubMed     Abstract available


    September 2020
  37. GUIL MJ, Soria C, Seijas M, Bianciotti LG, et al
    Central endothelin ETB receptor activation reduces blood pressure and catecholaminergic activity in the olfactory bulb of deoxycorticosterone acetate-salt hypertensive rats.
    Eur J Pharmacol. 2020 Sep 4:173543. doi: 10.1016/j.ejphar.2020.173543.
    PubMed     Abstract available


    August 2020
  38. CHEN Y, Yuan T, Chen D, Liu S, et al
    Systematic analysis of molecular mechanism of resveratrol for treating pulmonary hypertension based on network pharmacology technology.
    Eur J Pharmacol. 2020 Aug 13:173466. doi: 10.1016/j.ejphar.2020.173466.
    PubMed     Abstract available


  39. FONSECA DA SILVA RCMVA, Boeing T, Bolda Mariano LN, Somensi LB, et al
    The pathophysiology of acute gastric ulcer development in normotensive and hypertensive rats: A comparative study.
    Eur J Pharmacol. 2020 Aug 12:173469. doi: 10.1016/j.ejphar.2020.173469.
    PubMed     Abstract available


  40. BRAGA CL, Felix NS, Teixeira DE, Vieira JB, et al
    Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension.
    Eur J Pharmacol. 2020 Aug 11:173438. doi: 10.1016/j.ejphar.2020.173438.
    PubMed     Abstract available


  41. HEGAZY M, El-Shafey M, Abulsoud AI, Elsadek BEM, et al
    Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats.
    Eur J Pharmacol. 2020 Aug 1:173383. doi: 10.1016/j.ejphar.2020.173383.
    PubMed     Abstract available


    June 2020
  42. RODRIGUEZ JE, Ruiz-Hernandez A, Hernandez-DiazCouder A, Huang F, et al
    Chronic diabetes and hypertension impair the in vivo functional response to phenylephrine independent of alpha1-adrenoceptor expression.
    Eur J Pharmacol. 2020;883:173283.
    PubMed     Abstract available


  43. SHIMIZU S, Nagao Y, Kataoka T, Kamada S, et al
    Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats.
    Eur J Pharmacol. 2020 Jun 27:173313. doi: 10.1016/j.ejphar.2020.173313.
    PubMed     Abstract available


  44. DJOKIC V, Jankovic S, Labudovic-Borovic M, Rakocevic J, et al
    Pregnancy-induced hypertension decreases Kv1.3 potassium channel expression and function in human umbilical vein smooth muscle.
    Eur J Pharmacol. 2020 Jun 17:173281. doi: 10.1016/j.ejphar.2020.173281.
    PubMed     Abstract available


  45. AZHAR AS, Zaher ZF, Ashour OM, Abdel-Naim AB, et al
    2-Methoxyestradiol ameliorates metabolic syndrome-induced hypertension and catechol-O-methyltransferase inhibited expression and activity in rats.
    Eur J Pharmacol. 2020 Jun 13:173278. doi: 10.1016/j.ejphar.2020.173278.
    PubMed     Abstract available


  46. LIU Y, Shen W, Chen Q, Cao Q, et al
    Inhibition of RAGE by FPS-ZM1 alleviates renal injury in spontaneously hypertensive rats.
    Eur J Pharmacol. 2020 Jun 2:173228. doi: 10.1016/j.ejphar.2020.173228.
    PubMed     Abstract available


    May 2020
  47. OYAGBEMI AA, Omobowaleb TO, Adejumobi OA, Owolabi AM, et al
    Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.
    Eur J Pharmacol. 2020 May 15:173142. doi: 10.1016/j.ejphar.2020.173142.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: